Each day, millions of people pick up a prescription drug from their local pharmacy or mailbox. Most are affordable, with co-pays on average less than $7 for 90% of drugs. But for a growing number of ...

Hims & Hers Health (HIMS) on Thursday announced the launch of generic versions of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy semaglutide through its telehealth platform in Canada. The ...

The Trump administration is joining forces with Mark Cuban’s Cost Plus Drugs, Amazon Pharmacy, and GoodRx to add generic medications to the direct-to-consumer drug sales website, TrumpRx, in an ...

WASHINGTON, May 18 (Reuters) - U.S. President Donald Trump said on Monday that TrumpRx.gov, a government-backed website that lists discounted prescription drugs, will begin featuring generic medicines ...

The chief executive of generic-drug maker Sandoz SDZ-1.88%decrease; down pointing triangle Group expects the market for unbranded versions of popular weight-loss medicines to be big. Just how big, ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...

The FDA has approved the first generic versions of Farxiga, a drug used to treat Type 2 diabetes and reduce the risk of hospitalization for heart failure. The generic, dapagliflozin, is indicated to ...

The weight-loss world is on the brink of a major shake-up. Pharmaceutical companies in India will get the green light this weekend to start selling generic versions of Ozempic and Wegovy, with several ...

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions. By Rebecca ...

Over the last year, Sanofi has been busy reshaping itself to focus more on innovative drugs, including selling a controlling stake in its former consumer business and using those proceeds to strike a ...

After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S.